Leptomeningeal Metastases - Pipeline Insight, 2024

Leptomeningeal Metastases - Pipeline Insight, 2024

DelveInsight’s, “Leptomeningeal Metastases - Pipeline Insight, 2024” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Leptomeningeal Metastases pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Leptomeningeal Metastases: Understanding

Leptomeningeal Metastases: Overview

Leptomeningeal metastasis is a severe condition where cancer cells spread from the primary tumor to the meninges, the thin layers of tissue covering and protecting the brain and spinal cord. This can lead to inflammation of the meninges, accumulation of cerebrospinal fluid, and increased pressure in the brain. Leptomeningeal metastasis is commonly seen in patients with breast cancer, lung cancer, or melanoma, though it can occur with many types of cancer. It is also known as carcinomatous meningitis, leptomeningeal carcinoma, leptomeningeal carcinomatosis, meningeal carcinomatosis, meningeal metastasis, and neoplastic meningitis. Among solid tumors, breast cancer is the most frequent cause of leptomeningeal metastasis, followed by lung cancer (particularly small cell lung cancer) and melanoma, with gastrointestinal and primary central nervous system tumors also being common sources. Leptomeningeal disease (LMD) refers to the spread of cancer to the cerebrospinal fluid and the membranes surrounding the brain and spinal cord. This dissemination can happen through various mechanisms, such as direct seeding from brain tissue, the dura mater, and bone, as well as through hematogenous seeding and other pathways. Neurosurgical procedures and the choroid plexus may also facilitate this spread. Additionally, the upregulation of complement component 3 by cancer cells in the cerebrospinal fluid can compromise the blood-brain barrier, allowing plasma growth factors like VEGF to enter and promote tumor growth. LMD typically impacts areas such as the basal cisterns, posterior fossa, and cauda equina..

Diagnosis is challenging but can be achieved through neurological evaluation, brain and spinal magnetic resonance imaging, and cerebrospinal fluid cytology to detect malignant cells. Common symptoms include headaches, changes in vision, confusion, weakness, seizures, nausea, vomiting, and various neurological deficits. Treatment aims to control cancer growth and relieve symptoms, with options like targeted therapies and immunotherapies showing promise in certain cancers. Despite advancements in treatment modalities, survival rates remain poor after a diagnosis of leptomeningeal involvement.

Treatment for leptomeningeal metastases involves various modalities aimed at relieving symptoms and targeting cancer cells in the meninges and cerebrospinal fluid. Common treatments include radiation therapy, chemotherapy with drugs like methotrexate, thiotepa, and cytarabine, as well as targeted therapies like trastuzumab. Intrathecal pharmacotherapy, systemic pharmacotherapy, and focal radiotherapy are utilized to improve survival and maintain quality of life by delaying disease progression. Recent advancements include the use of intrathecal liposomal cytarabine and systemic therapy with targeted agents and immunotherapy, showing promise in improving outcomes for patients with leptomeningeal involvement.

""Leptomeningeal Metastases- Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Leptomeningeal Metastases pipeline landscape is provided which includes the disease overview and Leptomeningeal Metastases treatment guidelines. The assessment part of the report embraces, in depth Leptomeningeal Metastases commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Leptomeningeal Metastases collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Leptomeningeal Metastases R&D. The therapies under development are focused on novel approaches to treat/improve Leptomeningeal Metastases.

Leptomeningeal Metastases Emerging Drugs Chapters

This segment of the Leptomeningeal Metastases report encloses its detailed analysis of various drugs in different stages of clinical development, including Phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Leptomeningeal Metastases Emerging Drugs

• ANG-1005: AngioChem

ANG-1005 is a conjugate of angiopep-2 and paclitaxel, a drug that crosses the blood-brain barrier (BBB) and targets metastatic breast cancer. It binds to the low-density lipoprotein receptor-related protein (LRP)-1, which is abundantly expressed on tumor cells. This binding allows ANG-1005 to enter tumor cells by endocytosis, where it is then internalized and exerts its antitumor activity. Currently the drug is in Phase III stage of its clinical trial for the treatment of leptomeningeal metastases.

• Rhenium (186Re): Plus Therapeutics

Rhenium (186Re) obisbemeda is a novel injectable radiotherapy specifically formulated to deliver highly targeted high dose radiation in CNS tumors in a safe, effective and convenient manner to optimize patient outcomes. Rhenium (186Re) obisbemeda has the potential to reduce risks and improve outcomes for CNS cancer patients, versus currently approved therapies, with a more targeted and potent radiation dose. Rhenium-186 is an ideal radioisotope for CNS therapeutic applications due to its short half-life, beta energy for destroying cancerous tissue and gamma energy for live imaging. Currently the drug is in Phase I stage of its clinical trial for the treatment of leptomeningeal metastases.

Further product details are provided in the report……..

Leptomeningeal Metastases: Therapeutic Assessment

This segment of the report provides insights about the different Leptomeningeal Metastases drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Leptomeningeal Metastases
• There are approx. 5+ key companies which are developing the therapies for Leptomeningeal Metastases. The companies which have their Leptomeningeal Metastases drug candidates in the most advanced stage, i.e. Phase III include, AngioChem.
• Phases

DelveInsight’s report covers around 5+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Leptomeningeal Metastases pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical
• Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Leptomeningeal Metastases: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Leptomeningeal Metastases therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Leptomeningeal Metastases drugs.

Leptomeningeal Metastases Report Insights

• Leptomeningeal Metastases Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Leptomeningeal Metastases Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Leptomeningeal Metastases drugs?
• How many Leptomeningeal Metastases drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Leptomeningeal Metastases?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Leptomeningeal Metastases therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Leptomeningeal Metastases and their status?
• What are the key designations that have been granted to the emerging drugs?
 
Key Players
• AstraZeneca
• Kazia Therapeutics
• Plus Therapeutics
Key Products
• Osimertinib
• Paxalisib
• 186RNL